GeneDx Holdings Corp. Faces Securities Fraud Class Action as Schall Law Firm Seeks Lead Plaintiff
The Schall Law Firm, a Los Angeles-based national shareholder rights litigation firm, has reminded investors in GeneDx Holdings Corp. (NASDAQ: WGS) of an active class action lawsuit alleging violations of federal securities law.…
HONG KONG— June 29, 2026
The Schall Law Firm, a Los Angeles-based national shareholder rights litigation firm, has reminded investors in GeneDx Holdings Corp. (NASDAQ: WGS) of an active class action lawsuit alleging violations of federal securities law. The suit targets the genomic diagnostics company under Sections 10(b) and 20(a) of the Securities Exchange Act, the two provisions most commonly invoked in shareholder fraud claims — one covering market manipulation and misrepresentation, the other extending liability to controlling persons.
What the Lawsuit Alleges
The complaint rests on the twin pillars of Exchange Act securities litigation: Section 10(b), which prohibits fraudulent schemes and material misstatements in connection with the purchase or sale of securities, and Section 20(a), which holds those who control a violating entity jointly and severally liable. The Schall Law Firm did not disclose in its announcement the specific factual allegations underpinning the claims, the class period, or any quantification of alleged investor losses.
Opportunity to Lead
Shareholders who held WGS stock during the relevant period may apply to serve as lead plaintiff in the class action. The lead plaintiff role carries procedural significance: that investor, typically the one with the largest financial interest in the outcome, directs litigation strategy and selects lead counsel. The Schall Law Firm is actively soliciting WGS investors to step forward in that capacity.
What Investors Should Watch
For portfolio managers holding WGS, the filing is the first formal signal of litigation risk on the cap table. Class actions of this type — brought under Exchange Act provisions rather than state law — are adjudicated in federal court and, if certified, can represent a broad universe of shareholders. Whether the suit advances past a motion to dismiss will depend on the specifics of the underlying allegations, which the firm has yet to detail publicly. Investors with questions about their legal options have been directed to contact the Schall Law Firm directly.
Related reading
Source · 來源